Thyroid Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Thyroid Cancer Pipeline Drugs Market Report Overview
Thyroid cancer is a cancer that starts in the thyroid gland. Symptoms include a lump that can be felt through the skin on the neck, difficulty swallowing, pain in the neck and throat, and swollen lymph nodes in the neck. Predisposing factors include females, high levels of radiation, and inherited genetic syndromes. Treatment includes surgery and thyroid hormone therapy.
The Thyroid Cancer pipeline market report provides a comprehensive overview of the therapeutics under development for Thyroid Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Thyroid Cancer and features dormant and discontinued projects.
Key Targets | Proto Oncogene Tyrosine Protein Kinase Receptor Ret, Vascular Endothelial Growth Factor Receptor 2, Serine/Threonine Protein Kinase B Raf, Programmed Cell Death Protein 1, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor 3, Mast/Stem Cell Growth Factor Receptor Kit, Vascular Endothelial Growth Factor Receptor 1, Dual Specificity Mitogen Activated Protein Kinase Kinase 1, and Dual Specificity Mitogen Activated Protein Kinase Kinase 2 |
Key Mechanisms of action | Proto Oncogene Tyrosine Protein Kinase Receptor Ret Inhibitor, Vascular Endothelial Growth Factor Receptor 2 Inhibitor, Serine/Threonine Protein Kinase B Raf Inhibitor, Programmed Cell Death Protein 1 Antagonist, Epidermal Growth Factor Receptor Inhibitor, Vascular Endothelial Growth Factor Receptor 1 Inhibitor, Mast/Stem Cell Growth Factor Receptor Kit Inhibitor, Dual Specificity Mitogen Activated Protein Kinase Kinase 1 Inhibitor, and Dual Specificity Mitogen Activated Protein Kinase Kinase 2 Inhibitor |
Key Routes of Administration | Oral, Intravenous, Subcutaneous, Intratumor, Intravenous Drip, Parenteral, Intralesional, Intramuscular, Intraperitoneal, Intrathecal, and Intravesical |
Key Molecule Types | Small Molecule, Monoclonal Antibody, Cell Therapy, Synthetic Peptide, Gene-Modified Cell Therapy, Monoclonal Antibody Conjugated, Recombinant Protein, Fusion Protein, Gene Therapy, and Oncolytic Virus |
Major Companies | Novartis AG, Advenchen Laboratories LLC, Loxo Oncology Inc, AstraZeneca Plc, F. Hoffmann-La Roche Ltd, Pfizer Inc, CSPC Pharmaceutical Group Ltd, Jiangsu Hengrui Medicine Co Ltd, Merck & Co Inc, and AffyImmune Therapeutics Inc |
For more insights on Thyroid Cancer pipeline market, download a free report sample
Key Targets in the Thyroid Cancer Pipeline Drugs Market
In the Thyroid Cancer pipeline drugs market, the key targets are Proto Oncogene Tyrosine Protein Kinase Receptor Ret, Vascular Endothelial Growth Factor Receptor 2, Serine/Threonine Protein Kinase B Raf, Programmed Cell Death Protein 1, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor 3, Mast/Stem Cell Growth Factor Receptor Kit, Vascular Endothelial Growth Factor Receptor 1, Dual Specificity Mitogen Activated Protein Kinase Kinase 1, and Dual Specificity Mitogen Activated Protein Kinase Kinase 2.
Thyroid Cancer Pipeline Drugs Market, by Targets
For more target insights, download a free report sample
Key MoA in the Thyroid Cancer Pipeline Drugs Market
Proto Oncogene Tyrosine Protein Kinase Receptor Ret Inhibitor has the highest number of pipeline products followed by Vascular Endothelial Growth Factor Receptor 2 Inhibitor, Serine/Threonine Protein Kinase B Raf Inhibitor, Programmed Cell Death Protein 1 Antagonist, Epidermal Growth Factor Receptor Inhibitor, Vascular Endothelial Growth Factor Receptor 1 Inhibitor, Mast/Stem Cell Growth Factor Receptor Kit Inhibitor, Dual Specificity Mitogen Activated Protein Kinase Kinase 1 Inhibitor, and Dual Specificity Mitogen Activated Protein Kinase Kinase 2 Inhibitor.
Thyroid Cancer Pipeline Drugs Market Analysis, by MoA
To get more insights on key MoA, download a free sample report
Thyroid Cancer Pipeline Drugs Market Segmentation by RoA
The key routes of administration in the Thyroid Cancer pipeline drug market are oral, intravenous, subcutaneous, intratumor, intravenous drip, parenteral, intralesional, intramuscular, intraperitoneal, intrathecal, and intravesical. Oral has the maximum number of pipeline products.
Thyroid Cancer Pipeline Drugs Market Analysis, by RoA
To get more insights on key RoA, download a free sample report
Key Molecule Types in the Thyroid Cancer Pipeline Drugs Market
The key molecule types in the Thyroid Cancer pipeline drugs market are small molecule, monoclonal antibody, cell therapy, synthetic peptide, gene-modified cell therapy, monoclonal antibody conjugated, recombinant protein, fusion protein, gene therapy, and oncolytic Virus. Small molecule has the highest number of pipeline products.
Thyroid Cancer Pipeline Drugs Market, by Molecule Types
To get more insights on key molecule types, download a free sample report
Major Companies in the Thyroid Cancer Pipeline Drugs Market
The major companies in the Thyroid Cancer pipeline drugs market are Novartis AG, Advenchen Laboratories LLC, Loxo Oncology Inc, AstraZeneca Plc, F. Hoffmann-La Roche Ltd, Pfizer Inc, CSPC Pharmaceutical Group Ltd, Jiangsu Hengrui Medicine Co Ltd, Merck & Co Inc, and AffyImmune Therapeutics Inc.
Novartis AG: Novartis AG (Novartis) is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, immune disorders, and infections, among others. The company offers generic medicines and biosimilars through Sandoz. Novartis conducts research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR). The company operates through a network of subsidiaries and offices across the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.
Thyroid Cancer Pipeline Drugs Market, by Major Companies
For more company insights, download a free sample report
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Thyroid Cancer
- The pipeline guide reviews pipeline therapeutics for Thyroid Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Thyroid Cancer therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Thyroid Cancer therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Thyroid Cancer
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with a potentially strong product portfolio and create effective counter strategies to gain a competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Thyroid Cancer
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Thyroid Cancer pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Advanced Accelerator Applications SA
Advenchen Laboratories LLC
AffyImmune Therapeutics Inc
Akeso Inc
Alphamab Oncology
Applied Pharmaceutical Science Inc
Arch Oncology Inc
Aslan Pharmaceuticals Ltd
AstraZeneca Plc
Bayer AG
BeiGene Ltd
Beijing Konruns Pharmaceutical Co Ltd
Bicara Therapeutics Inc
BioMed Valley Discoveries Inc
Biosion Inc
Biovista Inc
Blueprint Medicines Corp
Boston Pharmaceuticals Inc
BridgeBio Pharma Inc
Bristol-Myers Squibb Co
C4 Therapeutics Inc
Calithera Biosciences Inc
CAS-Lamvac Biotech Co Ltd
Cello Therapeutics Inc
Centrose LLC
Chengdu Jinrui Foundation Biotechnology Co Ltd
Codiak BioSciences Inc
CSPC Pharmaceutical Group Ltd
CytImmune Sciences Inc
CytomX Therapeutics Inc
Daiichi Sankyo Co Ltd
Debiopharm International SA
Eisai Co Ltd
Eli Lilly and Co
Exelixis Inc
F. Hoffmann-La Roche Ltd
Faron Pharmaceuticals Oy
Genelux Corp
Gilead Sciences Inc
Gradalis Inc
Heilongjiang ZBD Pharmaceutical Co Ltd
Helsinn Group
Hutchison MediPharma Ltd
ImmunityBio Inc
ImmunoForge Co Ltd
Immunome Inc
IngenoVax LLC
InnoCare Pharma Ltd
Innovative Cellular Therapeutics Co Ltd
Intensity Therapeutics Inc
Iovance Biotherapeutics Inc
Jiangsu Carephar Pharmaceutical Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Jiangsu Vcare PharmaTech Co Ltd
Johnson & Johnson
Kemimedi Co Ltd
KinaRx LLC
Lepu Biopharma Co Ltd
Lotus Pharmaceutical Co Ltd
Loxo Oncology Inc
MaxiVAX SA
MedGene Therapeutics Inc
Merck & Co Inc
Molecular Targeting Technologies Inc
Novartis AG
Oncorus Inc
Ono Pharmaceutical Co Ltd
Pfizer Inc
Pionyr Immunotherapeutics Inc
Plexxikon Inc
Plus Therapeutics Inc
PRISM Pharma Co Ltd
Purple Biotech Ltd
Recordati SpA
Regeneron Pharmaceuticals Inc
Sanofi
Savoy Pharmaceuticals Inc
Shanghai De Novo Pharmatech Co Ltd
Shanghai Junshi Bioscience Co Ltd
Shouyao Holding Co Ltd
Sichuan Kelun Pharmaceutical Co Ltd
Sino Biopharmaceutical Ltd
SOTIO Biotech AS
SpringWorks Therapeutics Inc
Statera Biopharma Inc
Suzhou Neupharma Co Ltd
Suzhou SmartNuclide Biopharmaceutical Co Ltd
Suzhou Zelgen Biopharmaceutical Co Ltd
Synactix Pharmaceuticals Inc
Tarveda Therapeutics Inc
Theratechnologies Inc
Tiziana Life Sciences Plc
Tmunity Therapeutics Inc
TransThera Sciences (Nanjing) Inc
Trophogen Inc
Turning Point Therapeutics Inc
TYK Medicines Inc
Tyme Inc
Tyra Biosciences Inc
UBI Pharma Inc
UbiVac LLC
Vaccinex Inc
Vascular Biogenics Ltd
Visionary Pharmaceuticals Inc
Xiangxue Life Sciences
Xynomic Pharmaceuticals Holdings Inc
YaoPharma Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the Thyroid Cancer pipeline drug market?
In the Thyroid Cancer pipeline drugs market the key targets are Proto Oncogene Tyrosine Protein Kinase Receptor Ret, Vascular Endothelial Growth Factor Receptor 2, Serine/Threonine Protein Kinase B Raf, Programmed Cell Death Protein 1, Epidermal Growth Factor Receptor, Vascular Endothelial Growth Factor Receptor 3, Mast/Stem Cell Growth Factor Receptor Kit, Vascular Endothelial Growth Factor Receptor 1, Dual Specificity Mitogen Activated Protein Kinase Kinase 1, and Dual Specificity Mitogen Activated Protein Kinase Kinase 2.
-
What are the key mechanisms of action in the Thyroid Cancer pipeline drugs market?
In the Thyroid Cancer pipeline drugs market the key mechanisms of action are Proto Oncogene Tyrosine Protein Kinase Receptor Ret Inhibitor, Vascular Endothelial Growth Factor Receptor 2 Inhibitor, Serine/Threonine Protein Kinase B Raf Inhibitor, Programmed Cell Death Protein 1 Antagonist, Epidermal Growth Factor Receptor Inhibitor, Vascular Endothelial Growth Factor Receptor 1 Inhibitor, Mast/Stem Cell Growth Factor Receptor Kit Inhibitor, Dual Specificity Mitogen Activated Protein Kinase Kinase 1 Inhibitor, and Dual Specificity Mitogen Activated Protein Kinase Kinase 2 Inhibitor.
-
What are the key routes of administration in the Thyroid Cancer pipeline drugs market?
The key routes of administration in the Thyroid Cancer pipeline drug market are Oral, Intravenous, Subcutaneous, Intratumor, Intravenous Drip, Parenteral, Intralesional, Intramuscular, Intraperitoneal, Intrathecal, and Intravesical. Oral has the maximum number of pipeline products.
-
What are the key molecule types in the Thyroid Cancer pipeline drugs market?
The key molecule types in the Thyroid Cancer pipeline drug market are Small Molecule, Monoclonal Antibody, Cell Therapy, Synthetic Peptide, Gene-Modified Cell Therapy, Monoclonal Antibody Conjugated, Recombinant Protein, Fusion Protein, Gene Therapy, and Oncolytic Virus.
-
What are the major companies in the Thyroid Cancer pipeline drugs market?
In the Thyroid Cancer pipeline drugs market the major companies are Novartis AG, Advenchen Laboratories LLC, Loxo Oncology Inc, AstraZeneca Plc, F. Hoffmann-La Roche Ltd, Pfizer Inc, CSPC Pharmaceutical Group Ltd, Jiangsu Hengrui Medicine Co Ltd, Merck & Co Inc, and AffyImmune Therapeutics Inc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.